 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | regdanvimab inhalation (IN-006) / Inhalon, Celltrion
Journal: Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19. (Pubmed Central) - Oct 18, 2022
Finally, nebulized delivery of IN-006 resulted in 100-fold greater mAb levels in the lungs of rats compared to serum, in marked contrast to intravenously dosed mAbs. These results not only support our current efforts to evaluate the safety and efficacy of IN-006 in clinical trials, but more broadly substantiate nebulized delivery of human antiviral mAbs as a new paradigm in treating SARS-CoV-2 and other respiratory pathologies.
- | regdanvimab inhalation (IN-006) / Inhalon, Celltrion
New P1 trial: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of an Inhaled Antibody in Healthy Volunteers (EUDRACT) - Sep 17, 2021
P1, N=24, Not yet recruiting, Sponsor: Inhalon Biopharma, Inc.